(±)erso

ErSO is a selective activator of anticipatory unfolded protein response (UPR) via ERα receptor. ErSO can be used in studies about anti-cancer.

(±)-ErSO is the racemic form of ErSO. ErSO is a selective anticipatory activator of the unfolded protein response (a-UPR).

(S)-ErSO is an inactive dextrorotatory enantiomer of ErSO.

(Rac)-ErSO-DFP, a derivative of ErSO-DFP, is a selective small molecule that overactivates ERα+-dependent anticipatory unfolded protein responses. It functions as an Erα biomodulator and demonstrates efficacy against anti-estrogen receptor alpha-positive breast cancer, including resistant tumors.

ErSO-DFP is an expected activator of the unfolded protein response (a-UPR). erSO-DFP improves selectivity for oestrogen receptor alpha+ (ERα+) cancer cells with higher selectivity than ErSO. erSO-DFP has anti-tumour effects and significantly eliminates MCF-7 tumours in a mouse model.

ErSO-TFPy activates the sodium ion channel TRPM4, resulting in an imbalance of intracellular calcium and sodium ions. It exhibits low nanomolar-level cytotoxicity (IC50 = 5-25 nM) by inducing necrosis in ERα+ breast cancer cell lines. Additionally, ErSO-TFPy shows antitumor activity in mouse models.